Literature DB >> 21305339

Real-world practices to prevent venous thromboembolism with pharmacological prophylaxis in US orthopedic surgery patients: an analysis of an integrated healthcare database.

G J Merli1, E Malangone, J Lin, L Lamerato, L Stern.   

Abstract

Major orthopedic surgery patients are at high risk of venous thromboembolism (VTE) in-hospital and post-discharge. This study assessed real-world inpatient and outpatient thromboprophylaxis practices following knee or hip arthroplasty. Patients from the Henry Ford Health System aged ≥18 years undergoing knee and hip arthroplasty (January 1997-June 2007) were identified using Current Procedural Terminology codes from administrative databases. Patients with <18 months of continuous enrollment in the system's health maintenance organization or with a current diagnosis of atrial fibrillation were excluded. Both inpatient and outpatient pharmacological prophylaxis was assessed. The analysis included 1393 (58.5%) patients following knee arthroplasty and 989 (41.5%) following hip arthroplasty. Average length of hospitalization was 4.9 days over the study period, although the median stay decreased from 5 days in 1997 to 3 days in 2007. Of patients included, 72.7% received pharmacological prophylaxis only in the inpatient setting following knee arthroplasty and 73.9% following hip arthroplasty. Both inpatient and outpatient pharmacological prophylaxis was received by 12.5% of knee and 12.3% of hip arthroplasty patients. Total length of pharmacological prophylaxis fluctuated between 2 to 4 days between 1997 and 2005, but increased to 11.5 ± 9.0 days in 2007. Although the duration of prophylaxis has recently increased, considerable numbers of hip and knee arthroplasty patients only receive prophylaxis for part of the time period recommended by guidelines. Further efforts are required to ensure the recommended duration of thromboprophylaxis is prescribed to all patients and continued outpatient VTE prophylaxis is provided.

Entities:  

Mesh:

Year:  2011        PMID: 21305339     DOI: 10.1007/s11239-011-0554-0

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  15 in total

Review 1.  Prevention of venous thromboembolism.

Authors:  W H Geerts; J A Heit; G P Clagett; G F Pineo; C W Colwell; F A Anderson; H B Wheeler
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

2.  Preventing venous thromboembolism in US hospitals: are surgical patients receiving appropriate prophylaxis?

Authors:  Alpesh N Amin; Stephen Stemkowski; Jay Lin; Guiping Yang
Journal:  Thromb Haemost       Date:  2008-04       Impact factor: 5.249

Review 3.  Prevention of venous thromboembolism.

Authors:  G P Clagett; F A Anderson; W Geerts; J A Heit; M Knudson; J R Lieberman; G J Merli; H B Wheeler
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

Review 4.  Prevention of venous thromboembolism.

Authors:  G P Clagett; F A Anderson; J Heit; M N Levine; H B Wheeler
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

Review 5.  Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  William H Geerts; Graham F Pineo; John A Heit; David Bergqvist; Michael R Lassen; Clifford W Colwell; Joel G Ray
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

6.  Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty.

Authors:  Richard J Friedman; Alexander S Gallus; Fred D Cushner; Gordon Fitzgerald; Frederick A Anderson
Journal:  Curr Med Res Opin       Date:  2008-01       Impact factor: 2.580

7.  Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  William H Geerts; David Bergqvist; Graham F Pineo; John A Heit; Charles M Samama; Michael R Lassen; Clifford W Colwell
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

8.  Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry.

Authors:  D Warwick; R J Friedman; G Agnelli; E Gil-Garay; K Johnson; G FitzGerald; F M Turibio
Journal:  J Bone Joint Surg Br       Date:  2007-06

9.  Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study.

Authors:  Siân Sweetland; Jane Green; Bette Liu; Amy Berrington de González; Marianne Canonico; Gillian Reeves; Valerie Beral
Journal:  BMJ       Date:  2009-12-03

10.  Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start).

Authors:  A Amin; A C Spyropoulos; P Dobesh; A Shorr; M Hussein; E Mozaffari; J S Benner
Journal:  J Thromb Thrombolysis       Date:  2010-04       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.